Oppenheimer & Co. Inc. grew its stake in shares of Biogen Inc (NASDAQ:BIIB) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 57,604 shares of the biotechnology company’s stock after acquiring an additional 1,107 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Biogen were worth $18,351,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of BIIB. Ameriprise Financial Inc. increased its stake in shares of Biogen by 35.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,309,394 shares of the biotechnology company’s stock valued at $723,142,000 after acquiring an additional 600,384 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Biogen by 24.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,325,987 shares of the biotechnology company’s stock valued at $728,314,000 after acquiring an additional 450,207 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Biogen during the 3rd quarter valued at about $123,494,000. Jackson Square Partners LLC increased its stake in shares of Biogen by 9.3% during the 3rd quarter. Jackson Square Partners LLC now owns 2,249,253 shares of the biotechnology company’s stock valued at $704,286,000 after acquiring an additional 191,526 shares during the last quarter. Finally, Schroder Investment Management Group increased its stake in shares of Biogen by 61.9% during the 3rd quarter. Schroder Investment Management Group now owns 495,471 shares of the biotechnology company’s stock valued at $153,596,000 after acquiring an additional 189,501 shares during the last quarter. 88.11% of the stock is owned by institutional investors.

Shares of Biogen Inc (NASDAQ:BIIB) opened at $316.78 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07. Biogen Inc has a 1 year low of $244.28 and a 1 year high of $370.57. The stock has a market cap of $68,060.00, a P/E ratio of 26.60, a price-to-earnings-growth ratio of 1.62 and a beta of 0.75.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The firm had revenue of $3.31 billion during the quarter, compared to analyst estimates of $3.08 billion. During the same period last year, the business earned $5.04 EPS. The firm’s revenue was up 15.1% compared to the same quarter last year. equities research analysts forecast that Biogen Inc will post 24.88 EPS for the current fiscal year.

In other news, CEO Michel Vounatsos acquired 780 shares of the stock in a transaction on Friday, December 29th. The stock was bought at an average price of $320.55 per share, with a total value of $250,029.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alexander J. Denner acquired 30,000 shares of the stock in a transaction on Wednesday, November 29th. The stock was purchased at an average cost of $317.36 per share, with a total value of $9,520,800.00. Following the transaction, the director now directly owns 10,029 shares of the company’s stock, valued at $3,182,803.44. The disclosure for this purchase can be found here. Insiders acquired 31,560 shares of company stock valued at $10,020,858 in the last ninety days. 0.25% of the stock is owned by corporate insiders.

A number of research analysts have recently commented on the stock. Royal Bank of Canada reaffirmed a “hold” rating and set a $321.00 price objective on shares of Biogen in a research note on Tuesday, December 5th. Nomura upped their price objective on shares of Biogen from $355.00 to $420.00 and gave the company a “buy” rating in a research note on Saturday, December 30th. BidaskClub raised shares of Biogen from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Mizuho set a $400.00 target price on shares of Biogen and gave the stock a “buy” rating in a research report on Monday, November 13th. Finally, SunTrust Banks increased their target price on shares of Biogen to $392.00 and gave the stock a “buy” rating in a research report on Friday, January 26th. Eight analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $368.99.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/biogen-inc-biib-shares-bought-by-oppenheimer-co-inc/1857784.html.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.